US FDA Approves AbbVie Parkinson Drug

The US Food and Drug Administration has approved AbbVie treatment tavapadon for adults with Parkinson disease. The once-a-day pill will be sold under the brand name Juvmo following late-stage trial success.

Xurve View
Insights:
FILE PHOTO: A sign stands outside a Abbvie facility in Cambridge, Massachusetts, U.S., May 20, 2021.

United States health regulators approved ABBVIE INC's once-a-day pill Juvmo for Parkinson's disease on Friday afternoon. The treatment targets over 11 million patients worldwide who suffer from the progressive brain condition. The approval provides a key milestone for AbbVie's neurology portfolio following its acquisition of Cerevel Therapeutics.